Skip to main content
Ishan S Kamat on Muck Rack

Ishan S Kamat

As seen in: The Lancet, Texas Medical Center
Cardiology | MedTech Founder. Opinions my own. RT not an endorsement. He/him.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ishan S

Contact Ishan S, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Identifying Causative Microorganisms in Left Ventricular Assist Device Infections as a Guide for Developing Bacteriophage Therapy

|
By Ishan S Kamat, Harveen K. Lamba, Casey Hines-Munson, Samuel Hudson
| Texas Medical Center
BACKGROUND: As more left ventricular-assist devices (LVADs) are implanted, multidrug-resistant LVAD infections are becoming increasingly common, partly due to bacterial biofilm production. To aid in developing bacteriophage therapy for LVAD infections, we have identified the most common bacterial pathogens that cause LVAD driveline infections (DLIs) in our heart transplant referral center.
Open in Who Shared Issue with article?

Patient Characteristics and Outcomes of Type 2 Myocardial Infarction During Heart Failure Hospitalizations in the United States

|
By Salik Nazir, Ishan S Kamat, Robert W. Ariss, George V Moukarbel
| Texas Medical Center
BACKGROUND: Type 2 myocardial infarction (MI) is increasingly diagnosed in patients with heart failure (HF). A paucity of data exists pertinent to the contemporary prevalence and impact of type 2 MI in patients with HF. We studied the patient profiles and the prognostic impact of type 2 MI on outcomes of HF hospitalizations. METHODS: The Nationwide Readmission Database 2018 was queried for patients with HF hospitalizations with and without type 2 MI.
Open in Who Shared Issue with article?

Myocarditis With COVID-19 mRNA Vaccines

|
By Biykem Bozkurt, Ishan S Kamat, Peter Hotez, Ariza Sole A
| AHA/ASA Journals
Abstract Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations, especially in young adult and adolescent males. According to the US Centers for Disease Control and Prevention, myocarditis/pericarditis rates are ≈12.6 cases per million doses of second-dose mRNA vaccine among individuals 12 to 39 years of age.
Open in Who Shared Issue with article?
See all 4 articles